Racivir

Racivir
Systematic (IUPAC) name
4-amino-5-fluoro-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one
Clinical data
Routes of
administration
Investigational
Identifiers
CAS Number 137530-41-7
ATC code none
PubChem CID 454858
ChemSpider 400521
NIAID ChemDB 005245
Chemical data
Formula C8H10FN3O3S
Molar mass 247.25 g/mol

Racivir is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Pharmasset for the treatment of HIV.[1] It is the enantiomer of emtricitabine, a widely used NRTI, meaning that the two compounds are mirror images of each other.

Emtricitabine, the enantiomer of racivir and a widely used NRTI

References

  1. "Racivir". AIDSmeds.com. March 24, 2006. Retrieved March 21, 2008.


This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.